CNSP CNSP
Company Profile ↓Company Overview
CNSP (CNSP) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -28.10% |
| 6 Months: | +0.93% |
| 3 Months: | -24.48% |
| 1 Month: | +5.78% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 48.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -169.91K | -195.09K | -415.06K | -699.09K | -1.97M | -2.47M | -2.01M | -3.61M | -3.81M | -3.81M | -3.15M | -3.56M | -3.42M | -4.93M | -4.03M | -4.53M | -3.54M | -2.53M | -5.63M | -4.34M | -2.41M | -3.25M | -4.98M |
| Net Income | -309.70K | -257.48K | -193.20K | -211.50K | -431.71K | -706.65K | -1.97M | -2.47M | -2.01M | -3.61M | -3.81M | -3.81M | -3.15M | -3.57M | -3.42M | -4.93M | -4.02M | -4.52M | -3.54M | -2.53M | -5.61M | -4.30M | -2.37M | -3.22M | -4.94M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.14 | -2.44 | -2.67 | -2.56 | -2.59 | -51.86 | -54.14 | -1,020.48 | -4,049.20 | -153.20 | -18.93 | -6.42 | -5.76 | -7.30 |
| R&D Expense | - | - | 4.60K | 48.31K | 42.73K | 325.63K | 613.08K | 1.49M | 1.04M | 2.21M | 2.66M | 2.58M | 1.89M | 2.22M | 2.21M | 3.57M | 2.85M | 3.41M | 2.43M | 1.12M | 4.24M | 3.24M | 1.17M | 2.20M | 3.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -881.79K | -3.83M | -9.45M | -14.49M | -15.27M | -18.87M | -14.90M | -15.99M |
| Net Income | -7.39M | -3.88M | -9.46M | -14.50M | -15.27M | -18.85M | -14.86M | -15.85M |
| Diluted EPS | - | - | - | -16.50 | -11.22 | -12,509.11 | -466.89 | -35.75 |
| R&D Expense | 21.27K | 1.85M | 5.06M | 9.81M | 9.30M | 14.10M | 9.29M | 9.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 683.33K | 7.91M | 15.85M | 8.76M | 13.05M | 1.70M | 8.70M | 8.62M |
| Total Equity | -58.53K | -549.30K | 7.60M | 13.95M | 6.16M | 8.13M | -4.43M | 6.18M | 4.52M |
| Cash & Equivalents | - | 282.74K | 7.24M | 14.04M | 5.00M | 10.06M | 548.72K | 6.46M | 7.20M |
| Total Liabilities | - | 1.23M | 311.00K | 1.91M | 2.59M | 4.92M | 6.13M | 2.52M | 4.10M |
| Current Liabilities | - | 1.23M | 311.00K | 1.91M | 2.59M | 4.92M | 6.13M | 2.52M | 4.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -716.38K | -3.55M | -7.32M | -13.54M | -10.56M | -14.14M | -17.11M | -13.81M |
| Investing Cash Flow | 0 | -20.12K | -17.95K | -5.75K | -4.42K | -3.90K | -4.19K | -18.18K |
| Financing Cash Flow | 1.16M | 10.26M | 14.13M | 4.51M | 15.61M | 4.64M | 23.03M | 14.57M |
| Capital Expenditure | -0 | -20.12K | -17.95K | -5.75K | -4.42K | -3.90K | -4.19K | -18.18K |
| Free Cash Flow | -716.38K | -3.57M | -7.34M | -13.54M | -10.56M | -14.14M | -17.12M | -13.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 1,345.7% | -51.0% | -67.8% | -235.2% | -187.8% | 425.3% | -240.5% | -350.5% |
| ROCE % | 160.5% | -50.4% | -67.8% | -235.0% | -187.7% | 425.6% | -241.3% | -353.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNSP
Why Did CNSP Stock Surge 330% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmhtT2tNMHE4bjZSeWxuN01aM0VnVU1CdnRid1R5NWxYV0dMNHZIMExUM0pTUWFMbzJvVFd5dUJNbmlKOWJPRHNma2hWcjJQeVp4b1Ezc3QtNFE5R3RlYkZ3Y1UtR3NqWWttdGs4NXBwXzVOZ2YxV3h4ajF3bkg4UFhYTHpVRmpvLTFXZU…
Biotech CNS raises $22.5M to buy clinical-stage drug assets - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPSDMzc29BZEFYeWEwZ290OUU1ZUFHbENkNHcyYndVTHNyQWo3VXJETjVLem10TUxEVEQ1bm5VWWF3NlVBd2lLMVJpMWhzRkRna29UMEZHSmxPRl80Q0x5T2tGVTRJNGtNSm02Z3Y3TFhxNklZdlVMY3U1OVYxNUFWWG9Gb1RQWi1hb2M4Yn…
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMiugJBVV95cUxNVVhUbUhNZ2V4ZUFfbUtKeUVVUEZFTlZJbnRKMDRPX3dyc091UW5TSFNDcDd5VUcyMjdDUjZ5eXJqelZ1WXlxcmlfelZmbUV3WTRKblJjVUhVd0dWcDJtN29XUVdkdjFIWEM3d1VjNWxzUEgxR3N4TG5QWDRPa3dVMTczZHNkT0NiU2l0MU…
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBzbzdpcmRmWGZmSVBjQklQbjFoXzBvczJBWlA4N1JvMkI2NnoxSnYtby1XR3pNMEtKb01lVC0xbEFsa0FSUjZtbXRPWVp2ejJ6UWJtb0Itc1pXUVFXaE5qQ0I0a0JZa2dFeDdTZC1DdGNWWUZpbUFGc25R?oc=5" target="_blank">CNS…
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot - Benzinga
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNVkZ0SjExeGFOYTJ0bzZUY2tjZWZTUGdYVlp1NlM0bzk3U3gxMXZ6dC1NX2NMaHg2OVBKbVBuN29LbFZLSUVoTG12QWZjdy1Cc0xLVVk1Q1NyVjQ1LU1IUU9lRVlpc0dha1FBcGFMc2hZNEp3UFM4REoxZlRUakVSeVpOdG8zUWI1WjRLY2…
CNSP Stock Volatility Spikes As Traders Watch Key Levels - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQZFozaEYtMllwSTRCU19rdENwY0pxZEhTMkxQYXBQazFQSmJYc2FrM2VOWmFlcGhaVTlyNVVrR25hUDVJSFEwX3g4c1JPckJJMm5TX29BcktWT051MDMzRE9CNk9ER2VCNWZ5V195VjExejM0bFZZYmdqNk50Z3RQVQ?oc=5" target="_…
CNSP — Frequently Asked Questions
What is the current share price of CNSP?
As of 2026-08-05 17:25 PDT, CNSP trades at $5.40 on NASDAQ/NYSE. Its 52-week range is $2.13 to $10.57.
What is the P/E ratio of CNSP?
CNSP trades at a trailing price-to-earnings (P/E) ratio of -0.15.
Is CNSP a good stock to buy?
This page provides a data-driven analysis of CNSP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.